The Brazilian federal health regulatory agency, Anvisa, has voted to maintain the ban on electronic cigarettes in the country that has been in place since 2009.
The board members agreed to continue prohibiting the sales, imports and marketing of electronic cigarette products. They also approved further discussions on how to improve the implementation of the ban and reduce the demand for electronic cigarettes in the future.
The meeting lasted for over four hours, during which government officials, experts, and activists gave speeches. Only one person opposed the ban - a lawyer from Phimo International.
Despite the ban, electronic cigarettes are becoming increasingly popular in Brazil, particularly among young people. A recent telephone survey revealed that smokers make up approximately 12% of the country's total population, while 20% of Brazilians aged 18 to 24 use e-cigarettes.
The World Health Organization (WHO) has issued a warning in their latest global report on tobacco use, stating that e-cigarettes are becoming a gateway for young people to start using other nicotine products, such as traditional cigarettes.
This article is compiled from third-party information and is intended for educational purposes and communication only. The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
